Amlovin

Amlodipine

Method of action: Antianginal, Antihypertensive, Antispasmodic, Hypotensive, Vasodilator

Treatment option: Hypertension, Angina Pectoris, Prinzmetal Angina

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlovin

Quick Facts

Property	Description
Active ingredient	Amlodipine besylate
Form	Tablet (Oral formulation)
Pharmacological class	Dihydropyridine Calcium Channel Blocker (DHP-CCB)
Common use	Reducing vascular resistance and heart strain
Origin	Synthetic compound

Core Identity: Composition and Pharmacological Class

Amlovin is a prescription-only medicinal product, marketed under its specific trade name, that contains the synthetic active ingredient Amlodipine, typically formulated as the besylate salt. It is precisely classified as a Calcium Channel Blocker (CCB) that belongs to the dihydropyridine subclass. This means the medication is designed to primarily act on the walls of your blood vessels to promote relaxation.

The product is manufactured as a solid oral tablet intended for systemic administration. As a branded pharmaceutical containing Amlodipine, Amlovin is clinically recognized for providing the established benefits of its class and is often selected by healthcare providers when a specific manufacturer's formulation of the long-acting DHP-CCB is preferred. This differentiation at the brand level ensures consistency in its delivery and manufacturing standards.

Classification and General Purpose

The drug's function as a Calcium Channel Blocker directly relates to its general therapeutic purpose: achieving vasodilation, or the widening of the arteries. This occurs through the selective inhibition of calcium ion influx into the muscle cells lining the blood vessels.

By causing the arteries to widen, Amlodipine reduces the overall resistance to blood flow, known as peripheral vascular resistance. The overall effect of this classification is the reduction of peripheral vascular resistance, a core property of the medication. For example, this function is central in a common neutral use scenario where a patient requires sustained support to maintain appropriate vascular function, thereby decreasing the effort your heart needs to circulate blood throughout the body.

Regulatory References

What side effects are possible with Amlovin?

Possible side effects and safety information

The official safety profile for Amlovin (Amlodipine) is structured by government regulatory agencies to outline documented adverse effects, their established frequency, and specific constraints on use.

Category	Description (Regulatory Status)
Frequency Classification	Very Common (ge 1/10): Edema (Swelling). Common (ge 1/100 to <1/10): Headache, Dizziness, Somnolence, Palpitations, Flushing, Nausea, Abdominal Pain, and Fatigue.
System-Organ Classes	Adverse reactions are documented across various systems including Vascular, Nervous System, Cardiac, and Gastrointestinal Disorders.
Serious Reactions	Rare but clinically significant reactions documented include Hepatitis, Pancreatitis, Angioedema, and severe skin reactions such as Stevens-Johnson Syndrome. Worsening angina or Acute Myocardial Infarction can develop after starting or increasing the dose in certain at-risk patients.
Population Safety Notes	Hepatic Impairment: Clearance is decreased, resulting in prolonged elimination; caution and slow titration are required for patients with severe impairment. Older Adults: A lower initial dose is recognized due to potentially decreased clearance leading to increased systemic exposure.
Dose/Exposure Patterns	Edema (swelling) is the most common adverse reaction and is documented to be dose-related. Headache and somnolence are frequently reported particularly upon the initiation of treatment.
Safety Restrictions	Contraindications include known hypersensitivity to the dihydropyridine class, cardiogenic shock, and significant aortic stenosis. Symptomatic hypotension is possible, especially in patients with severe aortic stenosis.

Regulatory Safety Summary

The regulatory profile is dominated by Very Common and Common vascular and neurological adverse reactions, establishing a baseline of expected events.
The official documentation defines specific Serious Adverse Reactions, including severe skin and hepatic events, which represent the lowest frequency but highest severity risks.
The safety constraints explicitly address patients with conditions like hepatic impairment and severe aortic stenosis, defining limitations on use to manage the risk of increased exposure or symptomatic hypotension.

The official safety information formally structures the understanding of the medicine's risk by detailing the high incidence of generally non-serious, dose-related events alongside the mandated disclosure of rare, clinically serious adverse reactions. This regulatory classification ensures that the full spectrum of documented safety characteristics is communicated as required by government standards.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The officially documented overdose profile for Amlovin (amlodipine) centers on severe cardiovascular distress resulting from the drug's exaggerated effect on the blood vessels. Massive overdose is associated with excessive peripheral vasodilation, leading to marked hypotension [Source: FDA, EMA]. A secondary effect may include reflex tachycardia as the body attempts to compensate for the profound drop in blood pressure [Source: NIH MedlinePlus].

When to Seek Immediate Help

Immediate medical attention must be sought in all suspected cases of massive overdosage. Regulatory documentation explicitly states that management requires the urgent initiation of active cardiac and respiratory monitoring, along with frequent blood pressure measurements.

There is no known specific antidote. Management focuses on extensive supportive measures. Treatment is documented to involve providing cardiovascular support, including elevating the extremities and judiciously administering fluids. If hypotension is unresponsive to these measures, the use of vasopressors (such as phenylephrine) may be considered [Source: FDA]. Regulatory data also indicates that standard hemodialysis is not likely to be of benefit due to the medication's high protein binding.

Therapeutic Uses of Amlovin

What Amlovin Treats: Main Uses and Benefits

Amlovin is a medication generally used for managing symptoms related to systemic imbalance and symptoms linked to organ-specific functional stress. It is considered relevant for managing Hypertension and supportive care across conditions involving episodic or fluctuating manifestations, such as in Coronary Artery Disease (CAD). It is applied in clinical settings requiring support for these conditions.

The medication is generally applied in contexts where continuous support is needed for symptoms that create noticeable physiological strain, addressing conditions like Essential Hypertension, chronic stable angina, and vasospastic angina. The primary therapeutic benefit supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability across relevant patient groups.

Sustained Management of Chronic High Blood Pressure

This domain addresses conditions marked by increased physiological stress. The support provided helps address symptom clusters that may become intense or disruptive, which assists with maintaining functional stability when symptoms become more noticeable. It is applied in scenarios where additional management of discomfort is required, and plays a role in managing symptoms linked to organ-specific functional stress.

Quick Fact: Relief for Vascular Discomfort

Symptom Domain	Conditions Managed	Primary Benefit
Systemic Imbalance	Essential Hypertension	Supports general well-being during symptomatic phases.
Functional Stress	Chronic Stable Angina	Supports the patient by easing distress during episodes.

Eligibility and Restrictions for Use

The eligibility for Amlovin (Amlodipine) is determined by regulatory agencies, establishing both absolute prohibitions and specific restrictions based on patient population, age, and existing health status.

Populations That Cannot Use Amlovin (Contraindications)

Restriction	Population/Condition
Absolute Contraindication	Known sensitivity (hypersensitivity) to amlodipine or any dihydropyridine derivative.
Absolute Contraindication	Patients with severe hypotension, cardiogenic shock, and obstruction of the left ventricular outflow tract (e.g., high grade aortic stenosis).

Age- and Condition-Based Eligibility

Adults are eligible for all approved indications (hypertension and coronary artery disease).
Pediatric Use: Use is established for the treatment of hypertension in patients aged 6 years and older. However, use in children less than 6 years of age is officially designated as not established by regulatory authorities.
Conditional Use: Elderly patients and individuals with hepatic impairment require cautious initiation, often starting at the lowest possible dose due to the potential for decreased drug clearance. Renal impairment does not generally require a dosage adjustment.
Pregnancy and Lactation: Use during pregnancy is conditional, permitted only when the potential benefit is determined to justify the potential risk to the fetus. For nursing mothers, regulatory advice is to discontinue breastfeeding when administering the medication.

What should I know about interactions with other medicines?

Amlovin (Amlodipine) can interact with several other medications, which may alter the effects of either drug and increase the risk of side effects. It is essential to inform your healthcare provider about all prescription, over-the-counter medicines, and herbal supplements you are currently taking.

Drug Interactions

Some drugs can increase Amlovin concentration in the blood, potentially increasing the risk of low blood pressure (hypotension) or fluid retention (edema). These include certain antifungals (like ketoconazole and itraconazole) and some HIV protease inhibitors (like ritonavir).

Other medicines can lower Amlovin levels, making it less effective at controlling blood pressure. These may include certain antibiotics (like rifampicin) and anti-seizure drugs (like phenytoin or carbamazepine).

Drug Class	Potential Outcome
Statins (e.g., Simvastatin)	Increased risk of muscle side effects from the statin. Dose adjustment may be necessary.
Other Blood Pressure Medicines (e.g., Beta-blockers)	Increased risk of severely low blood pressure.
Immunosuppressants (e.g., Cyclosporine, Tacrolimus)	Increased concentration of the immunosuppressant in the blood.

Food and Product Interactions

Grapefruit juice should be avoided as it may increase the amount of Amlovin in the body, potentially enhancing its blood pressure-lowering effects and increasing the risk of side effects. St. John's wort may decrease Amlovin levels, potentially reducing its therapeutic effect. Discuss the use of herbal products with your doctor.

Mechanism of Action

Selective Blockade of Calcium Channels

Amlovin's action is governed by the specific inhibition of L-type Voltage-Dependent Calcium Channels (Cav1.2) found predominantly on the membranes of vascular smooth muscle cells (VSMCs). The drug functions as a calcium ion antagonist, binding to the channel and preventing the transmembrane influx of calcium ions (Ca^2+) into these cells. This action directly interferes with the universal signaling required for smooth muscle contraction.

Modulating Vascular Tone and Systemic Resistance

The immediate consequence of blocking calcium influx is the relaxation and widening of the peripheral arteries, a process known as vasodilation. This action modulates the overall vascular tone and systematically leads to a reduction of peripheral vascular resistance (PVR). This reduced resistance, in turn, modulates the force, known as cardiac afterload, that the heart must overcome to eject blood, adjusting circulatory hemodynamics.

Kinetics and Sustained Action Profile

The mechanism is characterized by a slow rate of association and dissociation with the channel binding site. These slow kinetics establish a sustained channel inhibition, supporting a consistent modulation of arterial muscle tone rather than an acute, rapid response.

Dosage and Administration Information

How to Use Amlovin

Amlovin is administered via the oral route using the tablet formulation, which is consistently available in strengths including 2.5 mg, 5 mg, and 10 mg. The medicine is designed for a long-term administration protocol, where adherence to a once-daily schedule is required to maintain consistent drug concentrations over a 24-hour period. To establish this necessary consistency, the tablet should be taken at the same time each day.

Standard Adult and Pediatric Dosing

The standard protocol for adults requires an initial dose of 5 mg once daily for conditions such as hypertension and angina. The subsequent maintenance dose is typically within the 5 mg to 10 mg range once daily. Doses are adjusted cautiously and should generally not exceed the 10 mg maximum daily dose. Dose adjustments are usually made at intervals of 7 to 14 days to ensure the full effect of the previous dosage level is achieved before any change.

Administration Conditions and Population Adjustments

Amlovin may be taken with or without food.

Specific dosing principles apply to certain populations. For older adults and patients with hepatic impairment, a lower initial dose of 2.5 mg once daily may be used, and titration must proceed slowly. Conversely, patients with renal impairment typically do not require an adjustment to the normal dosage schedule. For pediatric patients (6–17 years) being treated for hypertension, the maximum approved dose is 5 mg once daily.

If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

The research base for Amlodipine, the active ingredient in Amlovin, has been documented in numerous clinical trials, meta-analyses, and long-term observational studies. This research documents findings in conditions characterized by systemic or functional imbalance, including the contexts of essential hypertension and chronic stable angina.

Evidence for High Blood Pressure

Studies used large-scale Randomized Controlled Trials (RCTs) to explore Amlodipine for conditions involving physiological strain. Researchers monitored long-term, high-level endpoints like the incidence of major cardiovascular (CV) events (e.g., stroke or heart attack) with follow-up durations up to six years. Findings from pooled data describe patterns of CV event incidence that were monitored. Studies describe how blood pressure readings evolved in the observed populations.

Evidence for Chronic Stable Angina

Research is supported by multiple RCTs, often for patients whose episodic symptoms were not fully addressed by existing treatments. Studies monitored outcomes reflecting daily functioning, measuring exercise capacity and tracking the frequency of angina attacks and the usage of short-acting relief medication. Research monitored the incidence of hospitalization due to angina and the frequency of coronary revascularization procedures.

Research Context and Limitations

Amlodipine was evaluated over extended periods, typically spanning three to six years. This long-term evidence helps contextualize how blood pressure patterns evolved. Specific research has included pediatric patients (ages 6 to 17 years) and older adults with comorbidities. However, findings were mixed when evaluating its use in patients with certain types of severe heart failure. Furthermore, there is limited information for long-term outcomes that span decades, and evidence quality varies across certain comparative studies.

Key Studies & References Hypertension in adults: diagnosis and management (NICE Guideline NG136)

Frequently Asked Questions (FAQ)

Common questions about Amlovin (FAQ)

Q: What is the approved medical purpose of Amlovin?

According to official regulatory documents, Amlovin is indicated for the treatment of hypertension (high blood pressure). It is also approved for the symptomatic treatment of specific types of angina (chronic stable and vasospastic). Additionally, it is indicated to address the risk of hospitalization due to angina in certain patients with coronary artery disease.

Q: How quickly should I expect to see the effects of Amlovin?

Official drug information indicates that Amlovin has a gradual onset of action. While the medicine is designed for once-daily use to maintain consistent concentrations over 24 hours, the full blood pressure-lowering effect may take several days of continuous use to be observed.

Q: Why do some people experience swelling while taking Amlovin?

The medicine works by relaxing and widening peripheral arteries, which is a process known as vasodilation. Official documentation reports that swelling (edema), typically of the ankles or feet, is a very common side effect associated with Amlovin and is known to be dose-related.

Q: Does Amlovin affect my ability to drive or operate machinery?

Due to the risk of side effects such as dizziness and somnolence (drowsiness), official regulatory guidance suggests caution when driving or operating hazardous machinery until the effects of the medicine are known.

Q: Does Amlovin interact with alcohol?

Official drug information describes that using alcohol may have an additive effect with Amlovin in lowering blood pressure. The documentation indicates this effect may be associated with an increased risk of side effects such as lightheadedness or dizziness.

Q: Does Amlovin interact with common vitamins or supplements?

Official documentation describes that certain multivitamins with minerals may potentially reduce the effects of Amlovin. Regulatory documents suggest that all herbal products, supplements, and vitamins being taken should be discussed with a healthcare professional.

Q: Can Amlovin be taken with over-the-counter pain relievers like ibuprofen?

Official information notes that some Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers, may interact with Amlovin. Official warning statements describe that this type of interaction may be associated with an increased risk of certain side effects or reduced blood pressure-lowering effect.

Q: How does my diet relate to the effectiveness of Amlovin?

Regulatory guidance states that Amlovin may be taken with or without food. However, official documentation explicitly recommends avoiding grapefruit juice, as it is known to increase the level of the medicine in the body, which could enhance its effects.

Q: Can Amlovin affect my mood or mental state?

The official safety profile includes nervous system disorders as potential side effects. These reactions are described as including dizziness and somnolence (drowsiness).

Q: Is Amlovin safe to use during pregnancy, based on official information?

Official regulatory guidance concerning use during pregnancy states that the medicine is advised only if the potential benefit is considered to justify the potential risk to the fetus. This information indicates that the decision rests upon the balancing of potential risks and benefits.

Q: What are the official recommendations regarding Amlovin and breastfeeding?

Official documentation provides specific recommendations for nursing mothers. It advises that a healthcare professional should consider discontinuing nursing when the medicine is being administered.

How should Amlovin be stored and disposed of?

How to Store and Dispose of Amlovin (Amlodipine)

Amlovin tablets must be stored strictly according to the conditions defined in the official regulatory labeling to ensure product integrity and safety.

Official Storage and Disposal Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C.
Protection	Store in the original, tightly closed container. The product must be protected from moisture and excess heat.
Child Safety	Keep this medication out of the sight and reach of children at all times.
Disposal	Unused or expired medication should be disposed of by using a local drug take-back program. If unavailable, the FDA recommends flushing Amlovin to prevent accidental ingestion.